View Financial HealthPsykey 配当と自社株買い配当金 基準チェック /06Psykey配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.決済の安定と成長配当データの取得安定した配当: CEOSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CEOSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Psykey 配当利回り対市場CEOS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CEOS)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Healthcare Services)1.3%アナリスト予想 (CEOS) (最長3年)n/a注目すべき配当: CEOSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CEOSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CEOSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CEOSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 20:31終値2026/05/22 00:00収益2008/09/30年間収益2007/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psykey, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.
お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.
お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.
お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.
お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.